Prolx Pharmaceuticals Corp.
Patent Owner
Stats
- 4 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- May 12, 2011 most recent publication
Details
- 4 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 84 Total Citation Count
- Oct 20, 1994 Earliest Filing
- 12 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
7858657 Wortmannin analogs and methods of using same in combination with chemotherapeutic agentsSep 23, 08Dec 28, 10[C07D]
7446124 Wortmannin analogs and methods of using same in combination with chemotherapeutic agentsJul 11, 05Nov 04, 08[A61K]
5602278 N-oxides and derivatives of chlorambucil for treating hypoxic tumor cellsOct 20, 94Feb 11, 97[C07F, C07C]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2011/0110,941 Wortmannin Analogs and Methods of Using Same in Combination with Chemotherapeutic AgentsAbandonedNov 08, 10May 12, 11[A61K, A61P]
2010/0105,072 Methods of identifying respondents to hypoxia inducible factor 1-alpha inhibitorsAbandonedOct 30, 09Apr 29, 10[G01N]
7629128 Methods of identifying respondents to hypoxia inducible factor 1-α inhibitorsExpiredApr 17, 06Dec 08, 09[G01N, C07K]
7399785 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factorExpiredAug 30, 04Jul 15, 08[A61K]
2006/0104,902 Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapyAbandonedAug 17, 05May 18, 06[A61K]
2005/0049,309 Regulation of HIF protein levels via deubiquitination pathwayAbandonedJul 14, 04Mar 03, 05[A61K]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
